SCHEMBL3756161

SCHEMBL3756161

[c]1ncccc1-c1ccccc1N1CCCC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.41
ALDH1A1 P00352 2/20 0.41
MAPT P10636 2/20 0.41
EGFR P00533 1/20 0.41
RAF1 P04049 1/20 0.41
ALOX12 P18054 1/20 0.41
MAP2K1 Q02750 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
KEAP1 Q14145 1/20 0.40
PTGS2 P35354 1/20 0.39
HTR7 P34969 3/20 0.38
GAA P10253 2/20 0.37
HTR1A P08908 1/20 0.36
HTR2A P28223 1/20 0.36
HTR5A P47898 1/20 0.36
HTR6 P50406 1/20 0.36
NR1I2 O75469 2/20 0.35
SMARCA2 P51531 2/20 0.35
SMARCA4 P51532 2/20 0.35
PBRM1 Q86U86 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3760226 0.98 KEAP1 (0.42) MAPK1ALDH1A1MAPTEGFRRAF1
SCHEMBL3762324 0.97 HTR7 (0.38) MAPK1ALDH1A1MAPTEGFRRAF1
SCHEMBL3760250 0.86 HTR7 (0.55) ALDH1A1HTR7HTR1AHTR2AHTR5A
SCHEMBL3757770 0.78 NR1I2 (0.35) ALDH1A1MAPTL3MBTL1GAANR1I2
SCHEMBL3760255 0.76 NOS1 (0.35) ALDH1A1MAPTGAANR1I2SMARCA2
SCHEMBL3999407 0.75
SCHEMBL3759741 0.75 NR1I2 (0.33) ALDH1A1MAPTL3MBTL1NR1I2SMARCA2
SCHEMBL3761306 0.74 KDM1A (0.35) ALDH1A1MEN1KMT2A
SCHEMBL3751373 0.74 ALDH1A1 (0.47) ALDH1A1MAPTALOX12L3MBTL1HTR7
SCHEMBL3760644 0.73 TSHR (0.57) ALDH1A1L3MBTL1NPC1MEN1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029570-B1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-10-15 EP disclosed
US-8324204-B2 Fused thiophene derivatives as kinase inhibitors UCB PHARMA SA (BE) 2012-12-04 US disclosed
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-12-02 US disclosed
WO-2009122148-A1 FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS PI3K KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-10-08 WO disclosed
WO-2009071895-A1 FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
WO-2009071890-A1 TRICYCLIC KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
EP-2029570-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-04 EP disclosed
WO-2007141504-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2007-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors PIKFYVE, PI4KA, PIK3CA MAPK1 178/4885ALDH1A1 3061/4885MAPT 790/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.